Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

3(33.3%)

Early Phase 1

1(11.1%)

N/A

1(11.1%)

9Total

Phase 1(4)

Phase 2(3)

Early Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03686202Phase 2Active Not Recruiting

Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

Role: collaborator

NCT03838601Not ApplicableActive Not Recruiting

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

Role: collaborator

NCT05743777Phase 2Withdrawn

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT04602715Phase 2Unknown

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression

Role: lead

NCT03832400Phase 1Completed

Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)

Role: lead

NCT02865616Phase 1Completed

MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

Role: lead

NCT04052451Phase 1Completed

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder

Role: lead

NCT03660748Early Phase 1Completed

Safety and Efficacy of MET-3 in Obese Human Subjects

Role: lead

NCT04507971Phase 1Unknown

Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia

Role: lead

All 9 trials loaded